Cybin Inc Ordinary Shares CYBN
News
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Cybin Provides Corporate Update on Upcoming Clinical Milestones
Cybin Announces Completion of Previously Announced Share Consolidation
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
Psychedelic-medicine stocks drop after ecstasy's rocky day at the FDA
Psychedelic stock jumps as Steve Cohen's Point72 snaps up shares